Rosuvastatin fails to lower CV events and death in ESRD patients
Links shared publicly online about this topic.
- 2,150total visits
Rosuvastatin fails to lower CV events and death in ESRD patients
Finally—a group of people who do not seem to benefit from statins. In the AURORA trial, rosuvastatin did not ward off cardiovascular events in patients with end-stage renal disease on hemodialysis. Just why this is so remains a mystery, but investigators speculate it might be due to the high degree of arterial calcification.
View full resource at theheart.org
Tags: Cholesterol Medication, Kidney Health, Urinary System, Kidney Failure, Crestor, Mortality, Event
Most Recently Shared on March 31, 2009 at 2:34 pm By:
heartwire #acc09 Statins offer no cardiovascular protection for patients with end-stage renal di.. http://tinyurl.com/d6grs4
Advertisement
